• 제목/요약/키워드: immune-mediated disease

검색결과 201건 처리시간 0.024초

BIRB 796 has Distinctive Anti-inflammatory Effects on Different Cell Types

  • Ryoo, Soyoon;Choi, Jida;Kim, Jaemyung;Bae, Suyoung;Hong, Jaewoo;Jo, Seunghyun;Kim, Soohyun;Lee, Youngmin
    • IMMUNE NETWORK
    • /
    • 제13권6호
    • /
    • pp.283-288
    • /
    • 2013
  • The pro-inflammatory cytokines tumor necrosis factor-${\alpha}$ (TNF${\alpha}$) and interleukin (IL)-$1{\beta}$ are crucial mediators involved in chronic inflammatory diseases. Inflammatory signal pathways regulate inflammatory cytokine expression-mediated by p38 mitogen activated protein kinase (p38MAPK). Therefore, considerable attention has been given to p38MAPK as a target molecule for the development of a novel anti-inflammatory therapeutics. BIRB 796, one of p38MAPK inhibitor, is a candidate of therapeutic drug for chronic inflammatory diseases. In this study, we investigated the effect of BIRB 796 on inflammatory cytokine productions by lipopolysaccharide (LPS) in different immune cell types. BIRB 796 reduced LPS-mediated IL-8 production in THP-1 cells but not in Raw 264.7 cells. Further analysis of signal molecules by western blot revealed that BIRB 796 sufficiently suppressed LPS-mediated phosphorylation of p38MAPK in both cell types whereas it failed to block inhibitor of kappa B (I-${\kappa}B$) degradation in Raw 264.7 cells. Taken together, these results suggest that the anti-inflammatory function of BIRB 796 depends on cell types.

Interleukin-2/antibody complex expanding Foxp3+ regulatory T cells exacerbates Th2-mediated allergic airway inflammation

  • Hong, Sung-Wook;O, Eunju;Lee, Jun Young;Yi, Jaeu;Cho, Kyungjin;Kim, Juhee;Kim, Daeun;Surh, Charles D.;Kim, Kwang Soon
    • BMB Reports
    • /
    • 제52권4호
    • /
    • pp.283-288
    • /
    • 2019
  • $Foxp3^+$ regulatory $CD4^+$ T (Treg) cells play an essential role in preventing overt immune responses against self and innocuous foreign antigens. Selective expansion of endogenous Treg cells in response to the administration of interleukin (IL)-2/antibody complex, such as the IL-2/JES6-1 complex (IL-2C) in mice, is considered an attractive therapeutic approach to various immune disorders. Here, we investigated the therapeutic potential of IL-2C in allergic airway inflammation models. IL-2C treatment ameliorated Th17-mediated airway inflammation; however, unexpectedly, IL-2C treatment exacerbated Th2-mediated allergic airway inflammation by inducing the selective expansion of Th2 cells and type-2 innate lymphoid cells. We also found that IL-2 signaling is required for the expansion of Th2 cells in lymphoproliferative disease caused by Treg cell depletion. Our data suggest that IL-2C is selectively applicable to the treatment of allergic airway diseases depending on the characteristics of airway inflammation.

Recent Advances of Vaccine Adjuvants for Infectious Diseases

  • Lee, Sujin;Nguyen, Minh Trang
    • IMMUNE NETWORK
    • /
    • 제15권2호
    • /
    • pp.51-57
    • /
    • 2015
  • Vaccines are the most effective and cost-efficient method for preventing diseases caused by infectious pathogens. Despite the great success of vaccines, development of safe and strong vaccines is still required for emerging new pathogens, re-emerging old pathogens, and in order to improve the inadequate protection conferred by existing vaccines. One of the most important strategies for the development of effective new vaccines is the selection and usage of a suitable adjuvant. Immunologic adjuvants are essential for enhancing vaccine potency by improvement of the humoral and/or cell-mediated immune response to vaccine antigens. Thus, formulation of vaccines with appropriate adjuvants is an attractive approach towards eliciting protective and long-lasting immunity in humans. However, only a limited number of adjuvants is licensed for human vaccines due to concerns about safety and toxicity. We summarize current knowledge about the potential benefits of adjuvants, the characteristics of adjuvants and the mechanisms of adjuvants in human vaccines. Adjuvants have diverse modes of action and should be selected for use on the basis of the type of immune response that is desired for a particular vaccine. Better understanding of current adjuvants will help exploring new adjuvant formulations and facilitate rational design of vaccines against infectious diseases.

두경부에 국한된 표현형으로 발생한 면역글로불린 G4와 연관된 질환: 증례 보고 (Immunoglobulin G4-Related Disease Involving Various Head and Neck Regions: A Case Report)

  • 임준용;선우미옥
    • 대한영상의학회지
    • /
    • 제83권4호
    • /
    • pp.910-917
    • /
    • 2022
  • 면역글로불린 G4 (immunoglobulin G4; 이하 IgG4) 관련 질병은 한때는 장기별 별개의 질환으로 진단되었던 질환들을 근래에 공통적인 병리학적, 혈액학적 및 임상적 특징을 가지는 면역 매개 질환을 일컫는다. 이 분류의 질환은 다양한 장기를 침범할 수 있으며, 두경부 역시 침범할 수 있다. 두경부를 침범하였을 경우, 주로 눈물샘, 안와, 갑상선, 뇌하수체 및 뇌수막 등을 주로 침범한다. 이에, 초기 급성중이염과 유양돌기염으로 증상으로 내원한 65세 여자환자에서 안면신경, 뇌경막, 비인강과 경부임파절에 동시에 발생하여 자기공명영상과 조직검사로 진단된 IgG4 연관 질환에 대하여 증례 보고를 하고자 한다.

Traditional topical herbal therapies in psoriasis

  • Keseroglu, Havva Ozge;Gonul, Muzeyyen
    • 셀메드
    • /
    • 제4권4호
    • /
    • pp.23.1-23.8
    • /
    • 2014
  • Psoriasis is a common, chronic, recurrent, immune-mediated inflammatory disorder of skin. Although conventional topical and systemic therapies yield remission for a while, they carry a risk of many side effects that limit the long term use of these agents and the disease recurs generally in a short period of time after cessation of therapy. An increasing number of psoriatic patients are using herbal products as a treatment to control their disease with less side effects. Clinicians should be aware of plants used in psoriasis and side effects related with them. The aim of this article is to review the different herbs used in psoriasis treatment.

Pathology of C3 Glomerulopathy

  • Shin, Su-Jin;Seong, Yoonje;Lim, Beom Jin
    • Childhood Kidney Diseases
    • /
    • 제23권2호
    • /
    • pp.93-99
    • /
    • 2019
  • C3 glomerulopathy is a renal disorder involving dysregulation of alternative pathway complement activation. In most instances, a membranoproliferative pattern of glomerular injury with a prevalence of C3 deposition is observed by immunofluorescence microscopy. Dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) are subclasses of C3 glomerulopathy that are distinguishable by electron microscopy. Highly electron-dense transformation of glomerular basement membrane is characteristic of DDD. C3GN should be differentiated from post-infectious glomerulonephritis and other immune complex-mediated glomerulonephritides showing C3 deposits.

Mechanism of resistance acquisition and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children

  • Yang, Hyeon-Jong;Song, Dae Jin;Shim, Jung Yeon
    • Clinical and Experimental Pediatrics
    • /
    • 제60권6호
    • /
    • pp.167-174
    • /
    • 2017
  • Mycoplasma pneumoniae pneumonia (MPP) is one of the most common forms of community-acquired pneumonia in children and adolescents. Outbreaks of MPP occur in 3- to 7-year cycles worldwide; recent epidemics in Korea occurred in 2006-2007, 2011, and 2015-2016. Although MPP is known to be a mild, self-limiting disease with a good response to macrolides, it can also progress into a severe and fulminant disease. Notably, since 2000, the prevalence of macrolide-resistant MPP has rapidly increased, especially in Asian countries, recently reaching up to 80%-90%. Macrolide-resistant Mycoplasma pneumoniae (MRMP) harbors a point mutation in domain V of 23S rRNA with substitutions mainly detected at positions 2063 and 2064 of the sequence. The excessive use of macrolides may contribute to these mutations. MRMP can lead to clinically refractory pneumonia, showing no clinical or radiological response to macrolides, and can progress to severe and complicated pneumonia. Refractory MPP is characterized by an excessive immune response against the pathogen as well as direct injury caused by an increasing bacterial load. A change of antibiotics is recommended to reduce the bacterial load. Tetracyclines or quinolones can be alternatives for treating MRMP. Otherwise, corticosteroid or intravenous immunoglobulin can be added to the treatment regimen as immunomodulators to downregulate an excessive host immune reaction and alleviate immune-mediated pulmonary injury. However, the exact starting time point, dose, or duration of immunomodulators has not been established. This review focuses on the mechanism of resistance acquisition and treatment options for MRMP pneumonia.

Promotion of Remyelination by Sulfasalazine in a Transgenic Zebrafish Model of Demyelination

  • Kim, Suhyun;Lee, Yun-Il;Chang, Ki-Young;Lee, Dong-Won;Cho, Sung Chun;Ha, Young Wan;Na, Ji Eun;Rhyu, Im Joo;Park, Sang Chul;Park, Hae-Chul
    • Molecules and Cells
    • /
    • 제38권11호
    • /
    • pp.1013-1021
    • /
    • 2015
  • Most of the axons in the vertebrate nervous system are surrounded by a lipid-rich membrane called myelin, which promotes rapid conduction of nerve impulses and protects the axon from being damaged. Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS characterized by infiltration of immune cells and progressive damage to myelin and axons. One potential way to treat MS is to enhance the endogenous remyelination process, but at present there are no available treatments to promote remyelination in patients with demyelinating diseases. Sulfasalazine is an anti-inflammatory and immune-modulating drug that is used in rheumatology and inflammatory bowel disease. Its anti-inflammatory and immunomodulatory properties prompted us to test the ability of sulfasalazine to promote remyelination. In this study, we found that sulfasalazine promotes remyelination in the CNS of a transgenic zebrafish model of NTR/MTZ-induced demyelination. We also found that sulfasalazine treatment reduced the number of macrophages/microglia in the CNS of demyelinated zebrafish larvae, suggesting that the acceleration of remyelination is mediated by the immunomodulatory function of sulfasalazine. Our data suggest that temporal modulation of the immune response by sulfasalazine can be used to overcome MS by enhancing myelin repair and remyelination in the CNS.

A Combination of PG490 and Lipopolysaccharide Induce Apoptosis through Activation of Casapase-3 and Downregulation of cIAP1 and XIAP in Human Astroglioma Cell

  • Lee, Tae-Jin;Woo, Kyung-Jin;Park, Jong-Wook;Kwon, Taeg-Kyu
    • IMMUNE NETWORK
    • /
    • 제5권2호
    • /
    • pp.99-104
    • /
    • 2005
  • Background: Malignant gliomas are the most common primary tumors in the central nervous system. Methods: We investigated the combined effect of PG490 and LPS on the induction of the apoptotic pathway in human astroglioma cells. Results: Treatment of U87 cells with combination of 50nM of PG490 and $50{\mu}g/ml$ of LPS resulted in increased internucleosomal DNA fragmentation, cleavage of PLC-${\gamma}1$, and downregulation of cIAP1 and XIAP. The combination of LPS and PG490 treatment-induced apoptosis is mediated through the activation of caspase, which is inhibited by the caspase inhibitor, z-VAD-fmk. Also, release of cytochrome c was found in PG490 and LPS-cotreated U87 cell. Conclusion: Taken together, combination of PG490 and LPS appears to be a potent inducer of apoptosis in astrogliaoma cells, and might have some benefit in the treatment of glioma patients.

Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab

  • Jung, Hye-In;Kim, Hyun Jung;Kim, Ji-Min;Lee, Ju Yup;Park, Kyung Sik;Cho, Kwang Bum;Lee, Yoo Jin
    • Journal of Yeungnam Medical Science
    • /
    • 제38권1호
    • /
    • pp.70-73
    • /
    • 2021
  • Relapsing polychondritis (RP) is a rare, progressive immune-mediated systemic inflammatory disease of unknown etiology, characterized by recurrent inflammation of cartilaginous structures. Approximately 30% of RP cases are associated with other autoimmune diseases. However, the co-occurrence of RP and Crohn disease (CD) has rarely been reported. Herein, we present a 35-year-old woman diagnosed with RP and CD, who was refractory to initial conventional medications, including azathioprine and glucocorticoid, but who subsequently responded to infliximab (IFX). For both diseases, remission was sustained with IFX. There has been no previous report regarding the successful treatment of co-existing RP and CD with IFX.